Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PIII Study of Idebenone Initiated for DMD: Takeda
September 14, 2009
- Novartis Prepares Trial for New-Type Flu Vaccine with Adjuvant
September 14, 2009
- Ono Licenses Asimadoline from Tioga
September 14, 2009
- R&D NEWS IN BRIEF
September 14, 2009
- MEDICAL DEVICE NEWS IN BRIEF
September 14, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 14, 2009
- Additional Data Required on Alogliptin + Actos FDC as Well: Takeda
September 14, 2009
- DSP to Acquire Sepracor at US$2.6 Bil.
September 14, 2009
- REGULATORY NEWS IN BRIEF
September 14, 2009
- Hisamitsu Completes Acquisition of Noven Pharm.
September 14, 2009
- Unike, Houken Develop Generics Use Promotion Report System
September 14, 2009
- Janssen Enhances CNS Field with 370 MRs
September 14, 2009
- Pharmacists Should Be Allowed to Change Specifications/Dosage Forms at Their Own Discretion
September 14, 2009
- China's Essential Drug List May Hit Non-Chinese Drug Firms Operating in China
September 14, 2009
- JPA Member Pharmacies Continue to Sell OTC Drugs by Phone: Kenko.com
September 14, 2009
- Yano Research Predicts 6-9% NHI Price Cuts in April 2010
September 14, 2009
- Need for Importing New-Type Flu Vaccines Questioned
September 14, 2009
- Blopress Ranked as Best-Selling Drug in Japan in 1st Qtr: IMS Japan
September 14, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 14, 2009
- Market for RA Drugs to Expand to ¥195 Bil. in 2016: Fuji-Keizai
September 14, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…